Who are Elrantamab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elrexfio, Elrexfio, MAP0004, AK112, Carboplatin, Paxlitaxel, SAR408701, AK112, Gemcitabine, Cisplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/elrantamab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Elrantamab — Competitive Intelligence Brief

Elrantamab (elrantamab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific Antibody. Area: Oncology.

marketed Bispecific Antibody BCMA (B-cell maturation antigen) Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Elrantamab (elrantamab) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Elrantamab TARGET	elrantamab	Pfizer	marketed	Bispecific Antibody	BCMA (B-cell maturation antigen)
Elrexfio	elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
Elrexfio	Elranatamab	Pfizer	marketed	Bispecific antibody	BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells	2023-01-01
MAP0004	MAP0004	Allergan	phase 3	Bispecific antibody
AK112, Carboplatin, Paxlitaxel	AK112, Carboplatin, Paxlitaxel	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) + chemotherapy combination	PD-1 and LAG-3
SAR408701	SAR408701	Sanofi	phase 3	Bispecific antibody; CD40/4-1BB agonist	CD40 and 4-1BB (TNFRSF9)
AK112, Gemcitabine, Cisplatin	AK112, Gemcitabine, Cisplatin	Akeso	phase 3	Bispecific antibody (PD-1/LAG-3 inhibitor) combined with chemotherapy	PD-1 and LAG-3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific Antibody class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elrantamab — Competitive Intelligence Brief. https://druglandscape.com/ci/elrantamab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab